HEPATITISANTIVIRAL agentsCurrent treatment of chronic hepatitis B virus (HBV) infection, pegylated interferon-伪 (pegIFN-伪) and nucleos(t)ide analogue (NA), can suppress HBV replication, reverse liver inflammation and fibrosis, and decrease risks of cirrhosis and hepatocellular carcinoma, but ...
Besides, new therapies could be combined with other established therapies, to provide a functional cure from hepatitis B infection. Introduction The chronic infection of hepatitis B virus (HBV) represents a major global public health problem today. An estimated 254 million individuals worldwide are ...
Hepatitis B virus (HBV) is prevalent worldwide and is difficult to eradicate. Current treatment strategies for chronic hepatitis B ultimately seek to achieve functional cure (FC); however, the factors contributing to FC remain unclear. We aimed to investigate the gut microbiota profiles of patients...
Therapeutic goal of chronic hepatitis B is a "functional" cure of HBV infection, which is rarely achieved with currently available antiviral agents. Major obstacles to a functional cure are intricate stability of HBV cccDNA and dysfunctional anti-HBV immune response. Antiviral and immunotherapeutic stra...
Hepatitis B virus (HBV) infection continues to be a major public health issue worldwide. HBsAg loss is associated with functional remission and improved long‐term outcome, and is considered to be a "functional cure" (also referred to as clinical or immunologic cure) for chronic hepatitis B. ...
governments, academia and industry towards a potential functional cure have accelerated in the past decade, especially since the remarkable achievement of oral cures for chronic hepatitis C. However, many questions about HBV’s immunology, which we believe is key to achieving a functional HBV cure,...
Therapeutic goal of chronic hepatitis B is a “functional” cure of HBV infection, which is rarely achieved with currently available antiviral agents. Major obstacles to a functional cure are intricate stability of HBV cccDNA and dysfunctional anti-HBV immune response. Antiviral and immunotherapeutic st...
HBV treatment experience may also receive Gilead’s Vemlidy®(tenofovir alafenamide fumarate, TAF). The primary outcome of the study will be the proportion of patients achieving a functional cure, defined as an off-therapy loss ...
Additional immune activation data in those patients in Cohort A1 that achieved a functional cure will be presented by Dr. Emily Thi, Senior Director, Immunobiology and Biomarkers Research at Arbutus Biopharma in a poster titled, “Soluble Immune Biomarker Profiling of Chronic Hepatitis B Subjects Trea...
Cytokine and chemokine responses in the acute phase of hepatitis B virus replication in naive and previously vaccinated blood and plasma donors. J. Infect. Dis. 209, 845–854 (2014). Article CAS PubMed Google Scholar Kakimi, K. et al. Blocking chemokine responsive to gamma-2/interferon (...